APAC Cell & Gene Therapy Market

$5,998$9,998

Featuring 60 Cell & Gene Therapy companies from China, Taiwan, Korea, Japan, South Asia, SEA, and Australia! APAC Cell & Gene Therapy Market 2021 covers comprehensive information on parameters such as product pipeline, future expansion plans, technologies used, production capacity, temperature requirements, manufacturing capabilities, and SCM preferences. It also contains analysis on market growth, M&As, financial updates, upcoming facilities and more. It provides readers a closer look into companies such as Chugai, Tessa Therapeutics, Daewong Pharm, Eutilex, Carmine Therapeutics, Sumitomo Dainippon, Unicocell Biomed, JW Creagene, Takara Bio and more.

KEY TAKEAWAYS
  • Insights on production processes, equipment, logistics and SCM services various BioPharmas and CMOs currently and plan to employ.
  • Understand the facility expansion plans of key players in the APAC region.
  • Identify potential clients who would be interested in your latest technology or service.
Clear
 
product details
  • 1Table of Contents
  • 2Companies Mentioned
  • 3User Access

Section 1

  • Preface
  • Report Scope & Data Coverage
  • IMAPAC’s Research Methodology

Section 2 – Company-Wise Analysis

  • Company Overview
  • GMP Certifications
  • Facilities’ Size, Equipment, Capabilities etc.
  • Expansion Plans
  • Current Product Pipeline
  • Stage of Development
  • Production Capacity
  • Platform Technologies
  • Product Temperature Requirements
  • Preferred Delivery and SCM methods
  • Partnerships & Collaborations
  • Financial Performance
  • Company Highlights, News & Updates
  • Interviews

Section 3: Region-Wise Data & Analysis

  • Distribution of Cell & Gene Therapy Companies
  • Targeted Disease Types
  • Stage of clinical trial phase
  • Allogenic vs Autologous Therapies
  • Targeted Antigens

Section 4

  • Bibiliography
  • Disclaimer
  • About Us
  • Our Other Reports

Facilities: Greater China

  • Henlius Pharma
  • Innovent Biologics
  • Pfizer
  • Tonhua Dongbao
  • AlphaMab
  • Akeso Pharmaceuticals
  • Hanmi Pharma
  • Sinovac
  • BeiGene
  • Junshi Biosciences
  • Tot Biopharma
  • Hualan Biological Engineering

Facilities: Korea and Japan

  • Samsung Bioepis
  • Astellas
  • Celltrion
  • Chugai
  • Hanmi Pharma
  • Kyowa Hakko Kirin
  • Aprogen Biologiccs
  • Daiichi Sankyo

Facilities: India and Australia

  • Aurobindo
  • CSL Bering
  • Serum Institute of India
  • CSIRO
  • Enzene Biosciences
  • Stelis Biopharma

Facilities: Southeast Asia

  • Abbvie
  • GSK
  • AJ Biologics
  • Amgen
  • Novartis Thailand
  • Baxter
  • Takeda
  • Siam Biosciences

Single - User Access

This license grants the right of use of the purchased report to a single recipient only. You may access the material on your computer, as and when required, for your own personal use.

Multi - User Access

Upto 3 users: This license grants the right of use of the purchased report by upto 3 users of the same firm/enterprise.

Corporate Access

Unlimited user access (Within your organization): This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the number of users.

chat
Get In Touch

    padlock

    By clicking the "Submit" button, you are agreeing to IMAPAC's Privacy Policy.

    bag